Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

A systematic evaluation of multi-gene predictors for the pathological response of breast cancer patients to chemotherapy.

Shen K, Song N, Kim Y, Tian C, Rice SD, Gabrin MJ, Symmans WF, Pusztai L, Lee JK.

PLoS One. 2012;7(11):e49529. doi: 10.1371/journal.pone.0049529. Epub 2012 Nov 21.

2.

Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.

Naoi Y, Kishi K, Tanei T, Tsunashima R, Tominaga N, Baba Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S.

Cancer. 2011 Aug 15;117(16):3682-90. doi: 10.1002/cncr.25953. Epub 2011 Feb 8.

3.

Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.

West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH.

Breast Cancer Res. 2011;13(6):R126. doi: 10.1186/bcr3072. Epub 2011 Dec 8.

4.

[Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].

Yang D, Tong F, Cao Y, Liu P, Zhou B, Liu H, Qiao X, Zhang J.

Zhonghua Zhong Liu Za Zhi. 2002 May;24(3):303-5. Chinese.

PMID:
12515634
5.

Impact of grade, hormone receptor, and HER-2 status in women with breast cancer on response to specific chemotherapeutic agents by in vitro adenosine triphosphate-based chemotherapy response assay.

Koo JS, Jung W, Shin E, Lee HD, Jeong J, Kim KH, Jeong H, Hong SW.

J Korean Med Sci. 2009 Dec;24(6):1150-7. doi: 10.3346/jkms.2009.24.6.1150. Epub 2009 Nov 9.

6.

GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer.

Miyake T, Nakayama T, Naoi Y, Yamamoto N, Otani Y, Kim SJ, Shimazu K, Shimomura A, Maruyama N, Tamaki Y, Noguchi S.

Cancer Sci. 2012 May;103(5):913-20. doi: 10.1111/j.1349-7006.2012.02231.x. Epub 2012 Mar 1.

7.

Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.

Coskun U, Gunel N, Onuk E, Yilmaz E, Bayram O, Yamac D, Cihan A, Ucan B, Yildirim Y, Celenkoglu G, Ozkan S.

Neoplasma. 2003;50(3):210-6.

PMID:
12937855
8.

Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.

Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Toi M.

Jpn J Clin Oncol. 2011 Jul;41(7):867-75. doi: 10.1093/jjco/hyr081.

PMID:
21719750
9.

Genomics of adjuvant therapy for breast cancer.

Kim SR, Paik S.

Cancer J. 2011 Nov-Dec;17(6):500-4. doi: 10.1097/PPO.0b013e31823e5370. Review.

PMID:
22157294
10.
11.

DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.

Rodriguez AA, Makris A, Wu MF, Rimawi M, Froehlich A, Dave B, Hilsenbeck SG, Chamness GC, Lewis MT, Dobrolecki LE, Jain D, Sahoo S, Osborne CK, Chang JC.

Breast Cancer Res Treat. 2010 Aug;123(1):189-96. doi: 10.1007/s10549-010-0983-z. Epub 2010 Jun 26.

PMID:
20582464
12.

Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.

Kadra G, Finetti P, Toiron Y, Viens P, Birnbaum D, Borg JP, Bertucci F, Gonçalves A.

Breast Cancer Res Treat. 2012 Apr;132(3):1035-47. doi: 10.1007/s10549-011-1687-8. Epub 2011 Jul 27. Erratum in: Breast Cancer Res Treat. 2012 Jul;134(1):449-51.

PMID:
21792624
13.

Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.

Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L.

J Clin Oncol. 2004 Jun 15;22(12):2284-93. Epub 2004 May 10.

PMID:
15136595
14.

Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.

Yasojima H, Shimomura A, Naoi Y, Kishi K, Baba Y, Shimazu K, Nakayama T, Kim SJ, Tamaki Y, Noguchi S.

Eur J Cancer. 2011 Aug;47(12):1779-88. doi: 10.1016/j.ejca.2011.06.017. Epub 2011 Jul 7.

PMID:
21741827
15.

Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.

Ottosson S, Magnusson K, Hultborn R.

Anticancer Res. 1999 Sep-Oct;19(5C):4429-34.

PMID:
10650787
16.
17.

Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer.

Villman K, Blomqvist C, Larsson R, Nygren P.

Anticancer Drugs. 2005 Jul;16(6):609-15.

PMID:
15930887
18.

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators.

J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. doi: 10.1093/jnci/djn151. Epub 2008 May 27.

19.

p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.

Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L.

Clin Cancer Res. 2000 Jul;6(7):2751-8.

20.

Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.

Yagata H, Kajiura Y, Yamauchi H.

Breast Cancer. 2011 Jul;18(3):165-73. doi: 10.1007/s12282-011-0254-9. Epub 2011 Feb 3. Review. Erratum in: Breast Cancer. 2012 Oct;19(4):369.

PMID:
21290263

Supplemental Content

Support Center